Document:

ex-1018x202010xk

   Exhibit 10.18  [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED        3050 Spruce Street  St. Louis, MO 63103  Tel (800) 448-0471  Fax (314) 286-7817  www.safcglobal.net      Second Amendment to SGD-1006  Commercial Supply Agreement executed on 1 December 2010 and  First Amendment to Commercial Supply Agreement executed on  20 January 2014 (the “First Amendment”)(the Commercial Supply  Agreement together with the First Amendment, the “Supply Agreement”)    19 September 2016  Vaughn Himes  21823 30th Drive S.E.  Bothell, WA 98021    Dear Vaughn    This letter agreement (the “Second Amendment”) confirms the Parties’ agreement to amend the Supply Agreement to change the price  per gram/per Batch (the “Price”) for SGD 1006 set forth in Appendix C to the Supply Agreement. The purpose of the pricing rev ision  is to a) capture the cost of the [ * ]  used in the manufacture of SGD-1006, b) capture the operational efficiencies gained during the  manufacturing of the [ * ]  c) capture the increased labor and overhead costs in the [ * ] , and d) capture the [ * ]  inventory remaining  from production [ * ] . Beginning as of January 1, 2017, certain [ * ] , as listed in the second table below, that were previously provided  [ * ]  in accordance with cGMP, Applicable Laws and the Quality Agreement, and the [ * ] . Through 2016, these [ * ]  had been  provided by or purchased separately by [ * ] . In addition, effective as of January 1, 2017, any [ * ]  from each batch production will  now be owned by [ * ] .    The table below compares the current price per gram under the First Amendment with the Price per gram effective as of the Effective  Date of this Second Amendment.    SGD-1006 - 300 gm batch Price per gm  First Amendment to Commercial Supply Agreement executed on  20 January 2014 [ * ]   Second Amendment to Commercial Supply Agreement [ * ]       CONFIDENTIAL Page1 of 3  

 

2/3         [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED           The table below itemizes the components of the amended Price.  [ * ]     In addition to the [ * ]  in this Second Amendment, SAFC and Seattle Genetics agree to perform an analysis of the [ * ]  prior to  discussing any change to the Price for 2018 to further [ * ] .    The Price as set forth in this Second Amendment shall be effective as of the first date of Manufacture of the [ * ] .    Terms capitalized, but not defined, herein shall have the meaning ascribed to them in the Supply Agreement. This Second Amendment  shall be effective as of the date of the last signature below (the “Effective Date”). Except as set forth in this Second Amendment, all of  the terms and conditions of the Supply Agreement remain in full force and effect.    CONFIDENTIAL Page 2 of 3  

 

3/3         [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED         IN WITNESS WHEREOF, the parties have executed this Second amendment by their duly authorized representatives, effective as of  the Effective Date.    Agreed and accepted:    SAFC, INC SEATTLE GENETICS, INC.    By /s/ Mike Smith By /s/ Vaughn B. Himes       Name  Mike Smith Name Vaughn B. Himes       Title Site Director Title EVP       Date November 22, 2016 Date December 2, 2016       CONFIDENTIAL Page 3 of 3ex-1026x202010xk

                    Exhibit 10.26  [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED          SIXTH AMENDMENT  TO DEVELOPMENT AND SUPPLY AGREEMENT    Effective as of date of the last signature below, Abbott Laboratories, an Illinois corporation having a principal place of business at  100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and Seattle Genetics, Inc., a Delaware corporation having a principal  place of business at 21823 – 30th Drive Southeast in Bothell, Washington 98021 (“Seattle Genetics”) (individually the “Party” or  collectively the “Parties”) agree to the following terms and conditions (“Sixth Amendment”) as set forth below.  WHEREAS, the Parties entered into a Development and Supply Agreement with an Effective Date of February 23, 2004 for the  manufacture of a chimeric anti-CD30 AC10 monoclonal antibody known as cAC10 Bulk Drug Substance (the “Original Agreement”),  which also constitutes the antibody component of SGN-35 and the Parties subsequently entered into five amendments to the Original  agreement (the “First Amendment”, “Second Amendment”, “Third Amendment”, “Fourth Amendment” and “Fifth Amendment”,  respectively. Collectively the Original Agreement, the First Amendment, the Second Amendment, the Third Amendment, the Fourth  Amendment and the Fifth Amendment are hereinafter referred to as the “Agreement”); and  WHEREAS, the Parties desire to further amend the Agreement as herein provided as of the date hereof.     NOW, THEREFORE, in consideration of the mutual covenants and agreements contained here and for other good and valuable  consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:  1. I ncorporation of the Agreement. All capitalized terms which are used but not otherwise defined herein shall have the same  meanings as set forth in the Agreement, and the Agreement, to the extent not inconsistent with this Sixth Amendment, is incorporated  herein by this reference as though the same was set forth in its entirety. To the extent any terms and provisions of the Agreement are  inconsistent with the amendments set forth in Paragraphs 2 and 3 below, such terms and provisions shall be deemed superseded hereby.  Except as specifically set forth herein, the Agreement shall remain in full force and effect and its provisions shall be binding on the parties.  2. P rocess Development Work. The Parties agree that Abbott shall perform the activities set forth in Stage 6a of Attachment 1 hereto  pursuant to the terms and conditions of the Agreement.  3. P ayment Schedule. As compensation for the activities to be performed by Abbott pursuant to Attachment 1 hereto, Seattle  Genetics shall pay to Abbott the price established for each project stage on the dates set forth in Attachment 2. Billings associated with this  Sixth Amendment may be combined on the same invoice with other, regular Payment Schedule charges.  4. P roject References. All references to the Project set forth in the Agreement, with the exception of the Payment Schedule and  Facility Reservation Fee for the Project, shall also be deemed to apply to the activities performed by Abbott, pursuant to this Sixth  Amendment.  6. E ffectuation. The amendment to the Agreement contemplated by this Sixth Amendment shall be deemed effective as of the last  date written below upon the full execution of this Sixth  

 

  [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED    Amendment and without any further action required by the parties hereto. There are no conditions precedent or subsequent to the  effectiveness of this Sixth Amendment. All terms and conditions set forth in Agreement that are not amended hereby shall remain in full  force and effect. Any term of this Sixth Amendment may be amended with the written consent of both parties. From the date hereof, any  reference to the Agreement shall be deemed to refer to the Agreement as amended by this Sixth Amendment.  7. C ounterparts. This Sixth Amendment may be executed in two or more counterparts, each of which shall be deemed to be an  original, but all of which together shall constitute one and the same instrument. One or more counterparts of this Sixth Amendment may be  delivered by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart  thereof.  8. E ntire Agreement. This Sixth Amendment and exhibits hereto are the product of both of the parties hereto, and together with the  Agreement and exhibits thereto constitute the entire agreement between such parties pertaining to the subject matter hereof, and merge all  prior negotiations and drafts of the parties with regard to the transactions contemplated herein.  IN WITNESS WHEREOF, the parties have executed this Second Amendment as of the dates set forth below.    ABBOTT LABORATORIES SEATTLE GENETICS, INC.    By: /s/ Keith Kentala By: /s/ Clay B. Siegall       Name: Keith Kentala Name: Clay B. Siegall       Title:   General Manager, Commercial Operations Title: President & CEO       Date:   11/18/2010 Date: 11/8/2010     11/3/2011 2 CONFIDENTIAL  

 

  [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED    ATTACHMENT 1  PROJECT SCOPE  [ * ]     

 

  [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED  BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED    ATTACHMENT 2  PAYMENT SCHEDULE  [ * ]ex-1066xexecutivebonuspl

Exhibit 10.66   1.  SEAGEN  Senior Executive Annual Bonus Plan  This Senior Executive Annual Bonus Plan (the “Plan”) is intended to enhance stockholder value by  promoting a connection between the performance of Seagen Inc. (the “Company”) and the compensation of senior  executives of the Company, and to promote retention of participating senior executives.  1. Executives employed by the Company and its direct or indirect subsidiaries (“Affiliates”) at the  Vice President level and above (“Participants”) are eligible to receive annual bonuses for each calendar year (each,  a “Plan Year”) according to this Plan. The Plan will be administered by the Compensation Committee of the Board  of Directors of the Company (the “Committee”). The Committee shall have all powers and discretion necessary to  administer the Plan including any adjustments, amendments and modifications to the Plan or its application to all or  any participants, and to control its operation, and may delegate responsibilities to Company officers as it deems  appropriate. Participants are eligible to receive bonuses for each Plan Year based on their individual performance  and the Company’s performance during such Plan Year. A Participant who does not demonstrate a minimum level  of individual performance (50% or higher) during any Plan Year, however, will not be eligible for any portion of his  or her bonus for such Plan Year.  2. For each Plan Year, Company performance shall be determined by the Committee based on the  Company’s ability to meet or exceed Company goals for such Plan Year, as set forth by the Board of Directors of  the Company or the Committee, which may include without limitation such factors as: sales or commercial goals;  research, development and clinical activities, milestones and go/no go decisions; hiring, retention, development of  plans and other operational goals; strategic alliances and acquisitions; licensing or partnering transactions;  international expansion goals, government affairs and public policy goals; manufacturing and supply goals; quality  goals; regulatory goals; expense and cost reduction goals; debt reduction; improvement in or attainment of working  capital levels; financings; implementation or completion of projects or processes; and financial metrics, including  stock price performance, profitability, cash flow or net income. For clarity, the Committee may determine in its sole  discretion that the Company did not satisfactorily complete enough goals for the applicable Plan Year and in that  case, the Committee may determine that no bonus shall be paid to Participants for such Plan Year. For each Plan  Year, individual performance of the Participants who are senior executives on the Executive Committee and, if  applicable, any other employee who is an “officer” within the meaning of Rule 16a-1(f) under the Exchange Act  (each, an “Executive Officer”), shall be determined by the Committee upon review and recommendation to the  Committee by the Head of Human Resources and the Chief Executive Officer, except for the Chief Executive  Officer (whose bonus shall be based entirely on the Committee’s determination of the Company’s performance, as  provided in Section 3). For each Plan Year, individual performance of Participants who are not Executive Officers  (“Other Officers”) will be reviewed and determined by the CEO. In the case of all executives other than the CEO,  the determination of individual performance shall be based on the individual Participant’s satisfactory completion of  individual performance goals established for the applicable Plan Year and/or the individual Participant’s  contribution to the Company’s success in achieving the Company goals for such Plan Year, and the application of  guidelines established by the Committee.  3. The amount of a Participant’s bonus for each Plan Year is based on a target percentage of such  Participant’s annual base pay as of the last day of such Plan Year. This target percentage shall be determined at the  beginning of each Plan Year by the Committee in the case of Executive Officers or the CEO in the case of Other  Officers. The Chief Executive Officer’s final performance percentage for each Plan Year shall be based 100% on the  Company’s performance, as determined by the Committee in its sole discretion. For all Participants other than the  Chief Executive Officer, the final performance percentage for each Plan Year shall be based 50% on the Company’s  performance and 50% on each Participant’s individual performance.  For example, for an applicable Plan Year,  assuming the Company has met 130% of its goals, a Participant who is an Other Officer and has an individual  performance percentage of 160% based on his or her exceptional performance, has a target percentage of 25% and  has a base pay rate of $300,000 will receive a bonus of $108,750 for such Plan Year [(130% x 50% x $300,000 x  25%) + (160% x 50% x $300,000 x 25%) = $108,750]. For any Plan Year, the Company performance percentage  and/or the individual performance percentage may exceed 100% in the event the Company or the individual  Participant exceeds expected goals, provided that neither percentage may exceed 200%. Notwithstanding the  foregoing, if a Participant’s individual performance percentage is less than 100%, then regardless of the actual  

 

 2.  Company performance percentage, in calculating such Participant’s final bonus payout, the Company performance  percentage shall be capped at the Participant’s individual performance percentage. A Participant’s bonus for any  Plan Year may be paid in cash or stock or a combination of both at the discretion of the Committee. All  determinations and decisions made by the Committee or the CEO as applicable shall be final, conclusive and  binding on all persons and shall be given the maximum deference permitted by law.  4. To be eligible for a bonus for any Plan Year, a Participant must be on the Company’s payroll prior  to November 1 of such Plan Year and must be employed by the Company as of the date of payment of the bonus. A  Participant hired after commencement of any Plan Year shall be eligible for a pro-rated bonus for such Plan Year. A  Participant who, during any Plan Year, is promoted into a position with a higher bonus target will have a pro-rated  bonus based on his or her time in each position during such Plan Year and the applicable individual performance  targets for such positions for such Plan Year, but calculated based on the Participant’s annual base pay as of the last  day of such Plan Year.  5. A Participant who has taken an approved leave of absence pursuant to the Company’s or an  Affiliate’s policies as applicable of longer than 90 calendar days during any Plan Year shall receive a pro-rated  bonus for such Plan Year, calculated by excluding the number of days that exceed 90 calendar days during such Plan  Year that he or she was on an approved leave of absence.  6. A Participant who is on an approved leave of absence on the date the bonus payment for any Plan  Year is made will be eligible to receive a bonus for such Plan Year on the bonus payment date, provided that such  bonus will be pro-rated as calculated above if he or she was on an approved leave of absence for longer than 90  calendar days during such Plan Year.  7. This Plan was originally adopted on January 1, 2017 and was amended on February 4, 2019 and  February 9, 2021. Bonus payments for each Plan Year will be made by March 31st following the end of such Plan  Year.  8. The Company shall provide a copy of this Plan to each Participant upon request and communicate  to each Participant his or her target percentage for each Plan Year as determined by the Committee or the CEO, as  applicable, at the beginning of such Plan Year.  9. This Plan supersedes all prior bonus plans or any written or verbal representations regarding the  subject matter of this Plan and is the entire understanding between the Participant and the Company (and the  Affiliate who employs the Participant, as applicable) regarding the subject matter of this Plan. The payment of any  bonus under this Plan is fully discretionary.  Participation in this Plan for any Plan Year or series of Plan Years does  not and will not convey any entitlement whatsoever to participate in this Plan for any future Plan Year or in any  future plans or to the same or similar future bonus payments. The Committee may at any time amend, suspend, or  terminate this Plan, including amendment of the target percentages for each Participant and amendment so as to  ensure that no amount paid or to be paid hereunder shall be subject to the provisions of Section 409(a)(1)(B) of the  U.S. Internal Revenue Code of 1986, as amended (the “Code”). For the avoidance of doubt, it is intended that the  Plan satisfy the exemption from the application of Section 409A of the Code and the Treasury Regulations and other  guidance issued thereunder and any state law of similar effect provided under Section 1.409A-1(b)(4) of the  Treasury Regulations, and the Plan shall be administered and interpreted to the greatest extent possible in  compliance therewith.  10. The Company and its Affiliates shall withhold all applicable taxes from any bonus payment.  11. Nothing in this Plan shall interfere with or limit in any way the right of the Company or any  Affiliate (as applicable) to terminate any Participant’s employment or service at any time, with or without cause.  Nothing in this Plan should be construed as an employment agreement or an entitlement to any Participant for any  incentive payment hereunder.   12. This Plan and all awards shall be construed in accordance with and governed by the laws of the  State of Washington, without regard to its conflict of law provisions. In the event of a conflict between the local law  

 

 3.  applicable where a Participant is resident and the provisions of the Plan, the Company and its Affiliate(s) as  applicable will apply the Plan so as to comply with applicable laws.   13. Payments under this Plan shall be unsecured, unfunded obligations of the Company. To the extent  a Participant has any rights under this Plan, the Participant’s rights shall be those of a general unsecured creditor of  the Company.  14. Payments under this Plan shall be subject to recoupment, rescission, payback, cancelation or other  action, in each case, in accordance with (i) any clawback policy adopted by the Company (whether such policy is  adopted on or after the date of this Plan or required under applicable law), if applicable, and (ii) any such other  clawback, recovery or recoupment provisions set forth in an individual written agreement between a Participant and  the Company.  No recovery of compensation under such a clawback policy shall be an event giving rise to a  Participant’s right to resign for “good reason” or “constructive termination” (or similar term) under any program of,  or agreement with, the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]